User:Ci Mar-Gar/QASC
 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
The Quality in Acute Stroke Care Trial (QASC) was a research trial demonstrating that acute stroke patients who received improved management of fever, sugar and swallowing reflects, were 16% more likely to be alive or independent three months after their stroke. The study has generated significant interest amongst stroke research community following its publication in 2011 [1] due to the significant results of the trial showing the lowest? number needed to treat (NNT=6.4)known to date of stroke treatments.
BACKGROUND
THE TRIAL was a cluster randomized controlled trial (CRCT), examining the effect on death, disability and dependency of a multidisciplinary intervention to improve management of fever, hyperglycaemia and swallowing dysfunction following acute stroke in NSW, Australia.
A total of 1699 patients from 19 Australian Acute Stroke Units (ASUs) were recruited for this study; both pre intervention (n= 690 patients)and post intervention (n=1009). ASU’s were randomised to intervention (n=10) or control (n=9)sites. The intervention ASUs received evidence-based clinical treatment protocols for the management of fever, hyperglycaemia and swallowing dysfunction, in conjunction with multidisciplinary team building workshops, a standardised staff education program and engagement of local stroke unit coordinators. Control ASUs received only an abridged copy of the Australian acute stroke guidelines relevant to fever, hyperglycaemia and swallowing management. Patient outcome data were obtained via a 20 minute computerized assisted telephone interview 90-days post-admission. Intention to treat analysis was used adjusting for baseline data and clustering.
The results of the QASC trial showed that patients from control-group ASUs were significantly more likely to be dead or disabled at 90-days with a modified Ranking Scale (MRS)> 2, compared to patients from intervention ASUs (58% vs 42%; P=0.006) and to have lower SF-36 physical health scores (mean 42.5 vs 45.6; P=0.002).
This study is a landmark demonstrating a 16% absolute improvement in death or disability at 90-days for patients who received care in ASUs delivering the multidisciplinary intervention. It provides compelling evidence that multidisciplinary care to manage fever, hyperglycaemia and swallowing dysfunction can decrease death, disability and improve health status.
AFTER THE TRIAL
xx
STUDY INVESTIGATORS
The Trial was led by Prof Sandy Middleton, director of the Nursing Research Institute [1]from the Australian Catholic University
FURTHER READING
Xx
References
- ^ Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D'Este C, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. The Lancet. 2011;378 (9804):1699-706.